Novo Nordisk's oral weight loss drug receives EU recommendation for market approval, weight loss effect comparable to injections

Clinical trials have shown that obese or overweight patients lost an average of 16.6% of their body weight after adhering to the treatment, with results comparable to injectable medications, and one-third of patients lost more than 20% of their body weight. In addition, the drug's label now includes data showing a reduction in the risk of cardiovascular adverse events, with no restrictions on concomitant medications. Novo Nordisk plans to launch this product in certain markets outside the United States in the second half of 2026.